-
公开(公告)号：US20210115159A1
公开(公告)日：2021-04-22
申请号：US16951003
申请日：2020-11-18
Applicant: PFIZER INC. , RINAT NEUROSCIENCE CORP.
Inventor： Pavel STROP , Magdalena Grazyna DORYWALSKA , Arvind RAJPAL , David SHELTON , Shu-Hui LIU , Jaume PONS , Russell DUSHIN
Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.
-
2.发明申请公开(公告)号：US20170313787A1
公开(公告)日：2017-11-02
申请号：US15593259
申请日：2017-05-11
Applicant: PFIZER INC. , RINAT NEUROSCIENCE CORP.
Inventor： Pavel STROP , Magdalena Grazyna DORYWALSKA , Arvind RAJPAL , David SHELTON , Shu-Hui LIU , Jaume PONS , Russell DUSHIN
CPC classification number: C07K17/02 , A61K47/68 , A61K47/6803 , A61K47/6851 , A61K47/6889 , C07K16/30 , C07K2317/31 , C07K2317/73
Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.
-
Patent Agency Ranking
公开(公告)号：US20160257746A1
公开(公告)日：2016-09-08
申请号：US15160742
申请日：2016-05-20
Applicant: RINAT NEUROSCIENCE CORP.
Inventor： Shu-Hui LIU , Wei-Hsien HO , Pavel STROP , Magdalena Grazyna DORYWALSKA , Arvind RAJPAL , David Louis SHELTON , Thomas-Toan TRAN
CPC classification number: C07K16/28 , A61K38/08 , A61K47/6817 , A61K47/6849 , A61K47/6851 , A61K47/6859 , A61K47/6863 , A61K47/6869 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3046 , C07K16/3069 , C07K16/3076 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.
-
公开(公告)号：US20140357844A1
公开(公告)日：2014-12-04
申请号：US14460871
申请日：2014-08-15
Applicant: RINAT NEUROSCIENCE CORP.
Inventor： Shu-Hui LIU , Wei-Hsien HO , Pavel STROP , Magdalena Grazyna DORYWALSKA , Arvind RAJPAL , David Louis SHELTON , Thomas-Toan TRAN
CPC classification number: C07K16/28 , A61K38/08 , A61K47/6817 , A61K47/6849 , A61K47/6851 , A61K47/6859 , A61K47/6863 , A61K47/6869 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3046 , C07K16/3069 , C07K16/3076 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.
Abstract translation: 本发明提供特异性结合滋养层细胞表面抗原-2（Trop-2）的抗体。 本发明进一步提供了包含此类抗体的抗体缀合物，编码抗体的核酸，以及获得此类抗体的方法。 本发明还涉及这些抗体和Trop-2抗体缀合物用于治疗与Trop-2表达（例如癌症）如结肠，食管，胃，头颈部，肺， 卵巢癌或胰腺癌。
-
公开(公告)号：US20130122020A1
公开(公告)日：2013-05-16
申请号：US13670730
申请日：2012-11-07
Applicant: Rinat Neuroscience Corp.
Inventor： Shu-Hui LIU , Wei-Hsien HO , Pavel STROP , Magdalena Grazyna DORYWALSKA , Arvind RAJPAL , David Louis SHELTON , Thomas-Toan TRAN
IPC: C07K16/30
CPC classification number: C07K16/28 , A61K38/08 , A61K47/6817 , A61K47/6849 , A61K47/6851 , A61K47/6859 , A61K47/6863 , A61K47/6869 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3046 , C07K16/3069 , C07K16/3076 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.
Abstract translation: 本发明提供特异性结合滋养层细胞表面抗原-2（Trop-2）的抗体。 本发明进一步提供了包含此类抗体的抗体缀合物，编码抗体的核酸，以及获得此类抗体的方法。 本发明还涉及这些抗体和Trop-2抗体缀合物用于治疗与Trop-2表达（例如癌症）如结肠，食管，胃，头颈部，肺， 卵巢癌或胰腺癌。
-
公开(公告)号：US20180002428A1
公开(公告)日：2018-01-04
申请号：US15610417
申请日：2017-05-31
Applicant: PFIZER INC.
Inventor： Shu-Hui LIU , Flavia Mercer PERNASETTI , Weihsien HO
IPC: C07K16/28 , A61K49/00 , A61K47/68 , A61K39/395 , A61K39/00 , C07K14/715
CPC classification number: C07K16/2866 , A61K39/3955 , A61K47/6803 , A61K47/6809 , A61K47/6847 , A61K47/6849 , A61K47/6851 , A61K49/0002 , A61K2039/505 , C07H21/04 , C07K14/7158 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C12N15/09
Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
-
公开(公告)号：US20150037328A1
公开(公告)日：2015-02-05
申请号：US14449478
申请日：2014-08-01
Applicant: Pfizer Inc.
Inventor： Shu-Hui LIU , Flavia Mercer PERNASETTI , Wei-Hsien HO
CPC classification number: C07K16/2866 , A61K39/3955 , A61K47/6803 , A61K47/6809 , A61K47/6847 , A61K47/6849 , A61K47/6851 , A61K49/0002 , A61K2039/505 , C07H21/04 , C07K14/7158 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C12N15/09
Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
Abstract translation: 本发明提供结合趋化因子受体4（CXCR4）的抗体和相关分子。 本发明进一步提供包含此类抗体的抗体 - 药物偶联物，编码抗体的核酸，以及获得此类抗体的方法。 本发明还涉及使用这些抗体和抗CXCR4抗体 - 药物偶联物治疗与CXCR4功能或表达相关的疾病（例如癌症）如结肠，RCC，食管癌，胃癌，头部和/ 颈，肺，卵巢，胰腺癌或血液癌。
-
-
-
-
-
-
Search Results
7
records
(took 0.026 seconds)
